Macular Degeneration Clinical Trials

16 recruiting

Macular Degeneration Trials at a Glance

98 actively recruiting trials for macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Not Applicable with 19 trials, with the heaviest enrollment activity in Dallas, Sacramento, and Austin. Lead sponsors running macular degeneration studies include Hoffmann-La Roche, Medical University of Vienna, and AbbVie.

Browse macular degeneration trials by phase

Treatments under study

About Macular Degeneration Clinical Trials

Looking for clinical trials for Macular Degeneration? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 98 trials

Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting
Phase 3

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled56 locationsNCT06847542
Recruiting
Not Applicable

Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice

Age-Related Macular DegenerationDiabetic RetinopathyCataract+2 more
University of Copenhagen460 enrolled2 locationsNCT07015034
Recruiting

Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

Diabete MellitusRetina Vein OcclusionAge Macular Degeneration
Ataturk University180 enrolled1 locationNCT07550777
Recruiting

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

Geographic AtrophyAge-Related Macular Degeneration
University of California, San Francisco80 enrolled1 locationNCT07556406
Recruiting
Not Applicable

Defining Retinal Structures Using Hyperspectral Retinal Imaging

Age-Related Macular DegenerationDiabetic RetinopathyGlaucoma
Center for Eye Research Australia1,000 enrolled1 locationNCT07555574
Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.1,000 enrolled65 locationsNCT06779773
Recruiting
Phase 2Phase 3

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled20 locationsNCT07440225
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled100 locationsNCT07007065
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled50 locationsNCT04853251
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Age-Related Macular DegenerationIntermediate AMDAge-related Macular Degeneration (ARMD)
i-Lumen Scientific AUS PTY LTD100 enrolled10 locationsNCT06662162
Recruiting
Phase 2

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Phase 2

MMP-9 Inhibition for Recalcitrant Wet AMD

Exudative Macular Degeneration
University of Iowa50 enrolled1 locationNCT04504123
Recruiting

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Age-Related Macular Degeneration
University of Wisconsin, Madison1,000 enrolled14 locationsNCT06924021
Recruiting
Not Applicable

Direct Discrimination of Quantum States by the Human Eye

Age-Related Macular Degeneration
Centre for Eye and Vision Research50 enrolled1 locationNCT05913063